DORTMUND, Germany--(BUSINESS WIRE)--CellAct Pharma, a developer of innovative treatments for cancer, announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has granted orphan drug designation to the company’s CAP7.1, an adapted version of the well-established anticancer agent etoposide, for the treatment of biliary tract cancers. European Union (EU) orphan drug designation is given to products for the diagnosis, prevention or treatment of rare diseases that are life-threatening or very serious. A disease is defined as rare in the EU if it affects fewer than five in 10,000 people. Biliary tract cancer affects approximately 1.7 in 10,000 people in the EU. This is equivalent to a total of around 87,000 people.
Help employers find you! Check out all the jobs and post your resume.
